| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $5.4M | — | +56.6% |
| SG&A Expense | $2.5M | — | +0.4% |
| Operating Income | -$7.9M | — | -32.5% |
| Income Tax | $0 | — | — |
| Net Income | -$12.8M | — | -99.6% |
| EPS (Basic) | -$3.54 | — | -413.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $10.3M | +16.2% | +33.7% |
| Current Assets | $11.0M | +13.2% | +17.4% |
| Total Assets | $23.4M | +5.6% | +11.2% |
| Current Liabilities | $8.0M | +16.2% | +15.5% |
| Total Liabilities | $8.2M | +14.9% | -61.0% |
| Stockholders' Equity | $15.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.1M | — | -33.9% |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $7.6M | — | -4.8% |
| — |